The company will expand its site in High Point, North Carolina, by purchasing a 35,000-square-foot building it is currently leasing, as well as an adjacent 45,000-square-foot building. Both of these buildings will be fitted with kilo-scale and pilot-scale vessels.
This facility expansion is in response to the growing customer requirements for clinical supply manufacturing, according to the company. The center will also work on the development of new technologies and engineering solutions.
A spokesperson for Cambrex told us, “This gives us the opportunity to expand, adds additional capabilities and allows us the flexibility to meet future demand for our customers.”
Cambrex acquired PharmCore in 2016, now known as Cambrex High Point, to locate the company on this site.
In April of 2017, Cambrex announced that a $3.2m (€2.75m) construction project was completed on the site. This saw the completion of an 11,000-square-foot analytical laboratory and a new clinical manufacturing suite with 2000-liter reactors and a 0.6-square-meter dryer for clinical APIs.
“In April 2018, we announced a new analytical research & development laboratory, in addition to an investment in new continuous flow technology. In May 2018, we completed a pilot plant expansion at the High Point facility,” said the spokesperson.
In total, Cambrex has invested $5m in renovating the Cambrex High Point site. The company says that the High Point facility produces complex active pharmaceutical ingredients (APIs) and intermediates that require multi-step synthetic processes.
